Cancer Supportive Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Cancer Supportive Care Drugs Market Analysis

The cancer supportive care drugs market is expected to register a CAGR of nearly 3.56% during the forecast period (2022-2027).

The COVID-19 pandemic affected healthcare systems and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For Instance, in August 2020 the Authorea Journal article titled 'The Impact of COVID-19 Pandemic In Children With Cancer: A Report From Saudi Arabia' reported that cancer children on chemotherapy require regular outpatient assistance, and intermittent hospital admission, and support therapy for appropriate therapy delivery. It reported that in the studied population, 63% of patients reported a delay in treatment received during the COVID-19 pandemic. Also, out of these, the majority of patients (53.3%) reported hospital cancellation as the main reason for treatment or procedure delay during the COVID-19 lockdown and city curfew and 30.8% of patients reported non -availability of adequate PPE, lack of cancer support and shortage of medications as a major challenge faced during the pandemic. Many countries have suspended cancer screening programs for asymptomatic people due to the need to deploy healthcare personnel and resources to combat the pandemic. The Welsh and Scottish governments terminated breast, cervical, and bowel cancer screening programs in March 2020. Thus, owing to the shifted focus of research towards the development of COVID-19 vaccines, the market initially suffered a negative impact in terms of clinical trial activity but later came to recover.

Factors such as the increasing prevalence of cancer can be directly associated with the growth of this market. According to the American Cancer Society, in 2021 the estimated new numbers of cancer cases were 1.9 million and 608,570 cancer deaths in the United States. And in 2022 the same source projected that the new number of cancer cases will be 1.9 million and 609,360 cancer deaths in the United States. According to GLOBOCAN 2021, the new cancer cases that were diagnosed accounted for 19.3 million in 2021 globally, with 10.0 million deaths due to cancer. According to the WHO-World Health Organization, Cancer is the largest cause of mortality worldwide, accounting for almost 10 million fatalities in 2020, or nearly one in every six deaths, and approximately 400 000 children are diagnosed with the disease. Thus, increasing cancer would increase the demand for supportive drugs for treatment.

Rising disposable income and improved healthcare structure have also helped people to access cancer supportive care drugs, which is also helping this market grow. As per an August 2021 update, in Singapore, MediShield Life coverage changed from USD 3,000 a month to a range of USD 200 to USD 9,600 a month, based on the drugs used. The Government will also subsidize more cancer treatments and raise the criteria from a per capita monthly income of USD 2,800 to USD 6,500 for subsidies under the Medication Assistance Fund for certain high-cost drugs. The market players joining the patient access programs are boosting the growth of the market. For Instance, in February 2021, Biocon Biologics Ltd. signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs). Through this partnership, the company will enable access to Trastuzumab & Pegfilgrastim in Africa & Asia. The launch of new drugs by the market players in the regions is also boosting the growth of the market. For instance, in September 2021, Intas Pharmaceuticals launched Oral Azacitidine in India under the brand name Azadine-O for Acute Myeloid Leukemia. It is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. Such launches enhance the accessibility of cancer-supportive drugs and thus boosts the growth of the market segment.

However, other factors such as side effects from cancer-supportive drugs and stringent regulatory processes have also contributed as restraining factors to this market.

Cancer Supportive Care Drugs Market Trends

This section covers the major market trends shaping the Cancer Supportive Care Drugs Market according to our research experts:

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Segment is Expected to Register High Growth Over the Forecast Period

Cancer Supportive Care Drugs Industry Segmentation

Cancer supportive care drugs are used to mitigate the harmful side effects of cancer treatment by protecting certain cells or organs. The cancer supportive care drugs market is segmented by Drug Class (Granulocyte colony-stimulating factor, Erythropoiesis stimulating agent, Antiemetics, Bisphosphonates, Opioids, Non Steroidal Anti-Inflammatory Drugs, Topical, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.